Similarly, in Acute Lymphoblastic Leukemia (ALL), combining CD38 antibodies like daratumumab with chemotherapy regimens has yielded promising outcomes, particularly for patients with high CD38 expression [26]. Here, CD38 is linked to acute lymphoblastic leukemia.